Background. Clinical studies investigating topical hemostatic agents have not used standardized definitions for intraoperative bleeding. The Food and Drug Administration has recently sought use of a validated, clinician-reported scale to standardized bleeding sites in these clinical studies. The intent of a scale is to reduce patient risk, generate labeling claims, and allow comparisons among study results. We describe the development and validation of an intraoperative bleeding severity scale. Methods. A concept phase defined the framework of the scale. A feasibility and validation phase investigated the usability, clarity, relevance, and reliability (ie, intra-and interobserver concordance) among surgeons and surgical specialties as required by the Food and Drug Administration for the validation of a clinician-reported scale. Data were collected using an online tool. A total of 144 surgeons participated in the 3 phases. Results. The scale developed during the concept phase achieved an average intraobserver concordance of 0.97 and an interobserver concordance of 0.89 in the feasibility phase (N = 33); a concordance of 1.0 is perfect. The scale was refined and then achieved an average intraobserver concordance of 0.98 and an interobserver concordance of 0.91 in the validation phase with unanimous agreement by surgeons from multiple surgical specialties that the scale can be implemented into clinical studies (N = 102). Conclusion. This study validated an intraoperative bleeding severity scale for use in clinical studies investigating hemostatic agents. The scale was usable, clear, and clinically relevant with excellent reliability. The scale fulfills requirements of the Food and Drug Administration for a clinician-reported scale and can be used to generate clinically meaningful labeling claims. (Surgery 2017;161:771-81.) 
1
The use of hemostatic agents is a standard-of-care treatment in many surgical specialties [2] [3] [4] [5] [6] with increased use in major surgeries. 7, 8 Inadequate or incomplete hemostasis significantly increases the risk of perioperative morbidity and mortality, 9, 10 significantly increases health care costs and resource use, [11] [12] [13] [14] and is worsened by the use of antiplatelet and antithrombotic agents. [15] [16] [17] The need for hemostasis has led to the development of several topical hemostatic agents.
Clinical studies investigating topical hemostatic agents have not used standardized definitions or classifications for intraoperative bleeding severity or hemostasis, 18, 19 in part due to the lack of consensus in defining bleeding severity and in part due to the lack of requirement to do so. As a result, the labeling claims of hemostatic agents lack differentiation (eg, the appropriate severity or type of bleeding to be treated) (Online Supplement: eTable I). The generic labeling claims further impede surgeons' selection of the appropriate agent, conceal meaningful clinical differences, and lead to inefficiencies in surgery. 8 The use of a validated bleeding severity scale can establish standardized inclusion and exclusion criteria in a clinical study so that appropriate labeling claims can be generated. Furthermore, the use of standardized criteria ensures that patients are not subject to undue risks (eg, failed, delayed, or use of inappropriate treatments). With standardized criteria, patient and clinical study outcomes can also be compared to determine relative effectiveness.
Given these benefits, the United States Food and Drug Administration (FDA) now requires the use of a validated bleeding severity scale in clinical studies investigating hemostatic agents. Since no intraoperative bleeding severity scale has been validated for open surgical procedures and is applicable to multiple surgical specialties, the objective of this study was to develop and validate a clinician-reported scale (CRS) for intraoperative bleeding severity for use in clinical studies of hemostatic agents.
METHODS
The FDA provides guidance for the creation, development, and validation of a CRS. 20 Within this guidance, there are specific criteria that must be fulfilled for acceptability and validation (Table I) . These criteria were addressed throughout the development and validation in which surgeons from different surgical specialties developed and applied a scale to the full spectrum of bleeding as depicted in several videos.
Bleeding videos. Clinical videos lack standardized quality and the ability to predict the level of bleeding and measure the rate of blood loss; therefore, an animal model was required to create the videos. All animal activities were performed according to the Guide for the Care and Use of Laboratory Animals and the United States Animal Welfare Act in an institution accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International following Institutional Animal Care and Use Committee approval.
Pigs were selected due to their anatomical size and organ structure, which are similar to that of humans. 21 Eight male, domestic pigs were used to create videos representing the full range of blood loss across multiple surgical specialties and coagulopathic conditions (Fig 1) . Male pigs were used to avoid coagulation differences related to estrus. No adjunctive hemostatic agents were used in the videos (eg, oxidized cellulose, collagen, fibrin glue, etc).
For each bleeding model, the rate of blood loss was measured by collecting blood from each lesion with preweighed gauze for 6 seconds then calculating the difference and multiplying by 10 to obtain a rate in milliliters per minute, where 1 g of blood loss equated to 1 mL.
Videos were then selected based on representative rates of intraoperative blood loss, suitable cinematic quality, and clinical relevance (Online Supplement: eVideos 1-5). Each video was edited to be 15 seconds. Concept, feasibility, and validation study phases. The development and validation of the scale had 3 study phases: concept, feasibility, and validation. During each phase, surgeons were recruited based on the anatomic cavity in which he or she performs surgery according to American Medical Association surgical specialties. Surgeons were identified based on demonstrated involvement or interest in clinical studies of hemostatic agents. Surgeons were not selected based on previous consultancy agreements, product usage, or industry affiliations. Once recruited, surgeons were only allowed to participate in one of the phases to avoid participant overlap and creation bias. Three surgeons from the concept phase, however, were selected as advisors and participated throughout the validation (P.E.S., E.L., A.D.). All surgeons were recruited by BioMedCom Partners, Inc (New York, NY).
Concept study phase. This phase defined the conceptual framework and the intended use of the scale. A minimum of 3 surgeons from the 3 surgical cavities, 9 surgeons total, were recruited to participate. Each surgeon was board certified and a recognized leader within their field of surgery. This study phase was performed face-to-face, during which qualitative data were collected.
Feasibility study phase. This phase investigated the construct validity, ability to detect change, clarity, relevance, and response range of the scale developed during the concept phase and determined the videos needed for the validation phase. A minimum of 10 surgeons from each of the 3 surgical cavities, 30 surgeons total, were recruited to participate. Each surgeon was board certified and had a minimum of 5 years of postgraduate surgical experience. This study phase was performed face-to-face, during which quantitative and qualitative data were collected via an online data collection tool. The online data collection tool was designed and implemented by BioMedCom Partners, Inc.
Surgeons were didactically trained on the use of the scale and provided videos depicting different severities of bleeding specific to their own surgical cavity. Participants then individually used the scale to assess 15 videos relevant to their surgical cavity, after which they graded 15 additional videos from each of the other 2 surgical cavities. Each set of 15 videos contained 10 unique videos, of which 5 were repeated as duplicate videos. The 10 unique videos were used to assess interobserver agreement. The 5 duplicate videos were used to assess intraobserver agreement.
Validation study phase. This phase obtained statistically meaningful inter-and intraobserver agreement data using the scale and additional observational data supporting the scale's usability, clarity, and relevance. A minimum of 30 surgeons from each of the 3 surgical cavities, 90 surgeons total, were recruited to participate. Each surgeon was board certified and had a minimum of 5 years of postgraduate surgical experience. This study phase was performed entirely through the online data collection tool used in the feasibility phase, in which quantitative and qualitative data were collected.
Surgeons were self-trained on the scale through visual presentation and training videos of each level of severity. Surgeons then used the scale to grade 17 videos not specifically related to their surgical cavity. Of the 17 videos, the first 2 videos were not analyzed, the next 10 videos were unique, and the last 5 videos were repeats. The first 2 videos allowed familiarization with the online tool, video and question format, and data entry. The 10 unique videos were to assess interobserver agreement. The 5 duplicate videos were to assess intraobserver agreement. Statistical analysis. Agreement among surgeons and among surgical cavities (ie, interobserver agreement), and agreement within a surgeon and within a surgical cavity (ie, intraobserver agreement) was investigated. Interobserver agreement measures reproducibility, and intraobserver agreement measures repeatability of using a scale. Interand intraobserver agreement was analyzed using the Kendall's coefficient of concordance (Kendall's W) statistic. A Kendall's W of $0.7 is considered as "acceptable," $0.8 as "appreciable," $0.9 as "excellent," and 1.0 as "perfect" concordance. 22, 23 Box plots were used to present intraobserver Kendall's W statistics. Qualitative data were summarized using frequencies and percentages.
The sample size of the validation phase was based on an experimental power calculation after the feasibility phase, in which a sample size of 90 subjects assessing 10 videos achieves >80% power to detect a Kendall's W of 0.80 for interobserver agreement, and assessing 5 videos twice achieves >80% power to detect a Kendall's W of 0.80 for intraobserver agreement.
RESULTS
Concept study phase. Nine surgeons participated (Table II) . The average years of practice was 15 (standard deviation = 6.0). All surgeons reported using hemostatic agents in practice. The surgeons critically assessed the possible inclusion items and domains for a scale, which were then narrowed to those deemed most relevant (ie, anatomical appearance, intervention, qualitative description, visual appearance, and visually estimated rate of blood loss). The surgeons then defined the items and domains according to a quantitative structure, where grade 0 was "no bleeding" and grade 4 was "life-threatening bleeding."
Feasibility study phase. Thirty-three surgeons participated (Table II) . The average years of practice was 16.6 (7.6). All surgeons reported having used hemostatic agents.
All surgeons deemed a validated scale necessary for clinical studies, and 87.9% (n = 29) deemed it necessary for making labeling claims. Thirty-two surgeons (97.0%) agreed that the scale can be implemented for use in a clinical study. Thirty surgeons agreed that the scale was either "very" (n = 5, 15.2%) or "mostly" (n = 25, 75.8%) selfexplanatory, while 3 (9.1%) surgeons held that it was "not really," and none felt that it was "not at all" self-explanatory. All surgeons agreed that the scale reflected the range of bleeding site sizes and severities expected in clinical practice. Surgeon scores detected change across the videos, used the full response range, and responses changed appropriately to changes in severity (Table III) . The average intraobserver agreement for all surgeons was 0.97 for all types of videos, constituting "excellent" concordance (Table IV ). All Kendall's W values were >0.7 for each surgeon when considering all surgical cavity videos (Fig 2) . The overall interobserver agreement among all surgeons was 0.89 for all types of videos, constituting "appreciable" concordance (Table IV) .
Surgeons of different surgical specialties repeatedly and reproducibly assessed bleeding severities of their own surgical cavity and of other surgical cavities. For this reason, videos specific to each surgical cavity were not required for the validation phase. The item titled "Intervention" introduced confusion and differed among the specialties, so it was removed for the validation phase (Table V) .
Validation study phase. A total of 102 surgeons participated (Table II) . The average years of practice was 14.7 (7.6). All surgeons but one reported having used hemostatic agents.
All surgeons agreed that the scale can be implemented for use in a clinical study investigating the efficacy of a hemostatic agent. All surgeons agreed that the scale was either "very" (n = 53, 52.0%) or "mostly" (n = 49, 48.0%) selfexplanatory, while none held that it was "not really" or "not at all" self-explanatory. All surgeons but one (n = 101, 99.0%) stated that the scale was relevant for evaluating hemostasis in clinical studies. Ninety-six surgeons (94.1%) agreed that the scale reflected the range of bleeding site sizes and severities expected in clinical practice, while 6 (5.9%) did not. Ninety surgeons (88.2%) agreed that the scale uses objective terms, while the remaining 12 surgeons (11.8%) agreed that the scale "does not but it does not prevent use."
Similarly, 82 surgeons (80.4%) agreed that the scale uses nonoverlapping terms, while the remaining 20 surgeons (19.6%) agreed that the scale "does not but it does not prevent use." For surgeons who perform minimally invasive surgery, 79 of 99 (79.8%) stated that the scale can be applied "as is," while the remaining 20 (19.6%) stated that it can be applied "with modification." Of the 12 videos presented, 8 were determined to depict a clinical bleed by 92 or more surgeons ($90.2%), 1 video by 63 surgeons (61.8%), and the remaining 2 videos were not determined to depict a clinical bleed. These 2 videos were assessed as a grade 0 ("No bleeding"), so the videos were not considered as depicting a bleed by the majority of surgeons.
The intraobserver agreement among all surgeons was 0.98, constituting "excellent" concordance (Table IV) . All Kendall's W values were >0.7 for each surgeon (Fig 2) . The overall interobserver agreement among all surgeons was 0.91, constituting "excellent" concordance (Table IV) .
DISCUSSION
We describe the concept, development, and validation of a bleeding severity scale for use in clinical studies to generate labeling claims. The scale fulfilled all essential criteria required for a CRS with unanimous agreement to implement it into clinical studies. The usability, clarity, and relevance of the scale demonstrate the construct validity of the scale. And, the intra-and interobserver agreement demonstrate the reliability (ie, repeatability and reproducibility) of the scale. As a result, the scale is a validated means to establish labeling claims, standardize inclusion and exclusion criteria, and evaluate bleeding severity in open surgical procedures consistently across all surgical specialties in clinical studies. This scale addresses the FDA's request for a bleeding severity CRS that is also deemed necessary by surgeons.
In prospective clinical studies investigating safety and effectiveness of hemostatic agents, bleeding severity is not defined consistently, and different levels of bleeding are deemed The entire response range was used by 33 surgeons assessing 10 unique videos from 3 different surgical cavities. Surgeon responses changed appropriately with changes in the bleeding severity demonstrating that the scale can detect change. The listed video order represents the order the videos were presented to surgeons. Data are listed as number of respondents (percent).
appropriate for the same control agent. 18, 19 The definitions used in these studies and the chosen acceptable level of bleeding for the control agent are not known to be validated. As a result, the studies are not comparable and the results cannot be compared due to the different use of the same control agent. The use of the developed scale can be used to establish inclusion and exclusion criteria appropriate for a control agent to standardize study designs. Doing so reduces patient risk of experiencing intraoperative blood loss or postoperative complications due to hemostatic agent failure.
In establishing the inclusion and exclusion criteria, a clinical study can target a specific bleeding severity level(s) to generate labeling claims specific to that level of bleeding severity. Alternatively, a scale can set a defined level of expected hemostatic performance, such as was developed for intraoperative surgical staplers. 24 The scale developed by Siegel et al 24 to evaluate the efficacy of surgical staplers achieved a Kendall's W for intraobserver agreement of 0.95 and interobserver agreement of 0.85 based on 154 surgeons. The scale has since been used to evaluate new surgical staplers. 25 While Siegel et al 24 demonstrated reliability of their scale, they did not report on the validity of their scale (eg, construct validity, clarity, usability).
In addition to the utility of a validated bleeding severity scale for use in human clinical studies, the scale can be used to standardize preclinical animal models for the development and comparison of hemostatic agents. The 2 bleeding severity scales used in animal models are not validated, though they are considered to be clinically relevant in scientific literature. 26, 27 Jackman et al 26 designed a 5-point, Likert-type scale to evaluate the efficacy of harmonic scalpels, where 0 is "no hemostasis" and 4 is "dry." The scale's applicability is limited to the efficacy of harmonic scalpels. Adams et al, 27 however, designed a scale to evaluate the efficacy of In the feasibility phase, use of the Bleeding Severity Scale by 33 surgeons achieved "Excellent" intraobserver agreement and "Appreciable" interobserver agreement. Surgeons assessed 10 unique videos per surgical cavity to determine interobserver agreement and 5 videos twice per surgical cavity to determine intraobserver agreement. In the validation phase, 102 surgeons achieved "Excellent" concordance status for intraobserver and interobserver agreement. Surgeons assessed 10 unique videos to determine interobserver agreement and 5 videos twice to determine intraobserver agreement. A Kendall's coefficient of concordance (Kendall's W) of 1.0 is "Perfect" agreement.
hemostatic agents. The scale is a 6-point, pictorial scale of bleeding severity, where 0 is "no bleeding" and 4 is "severe." The scale was refined to remove a "0.5" severity level, which increased its use and acceptance. [28] [29] [30] [31] This preclinical scale has limited applicability beyond the lesion type described in these studies. Outside the use of the validated scale in research to standardize animal models, the scale can also provide context for residents and junior faculty who are learning hemostatic agent algorithms and surgeons who are unclear on when to use which hemostatic agent. Strengths. A development process continually involving surgeons and a validation process involving surgeons from multiple surgical specialties are clear strengths. Interestingly, surgeons do not intuitively understand, interpret, and use CRSs consistently. The intra-and interobserver agreement of the scale developed in the concept phase increased from the feasibility to the validation phase after changes to the scale. The changes increased the usability of the scale leading to unanimous agreement that it can be implemented into a clinical study. In addition, the scale fulfilled all FDA criteria for a CRS.
Surgeon assessments detected change appropriately with changes in the known bleeding rate and used the entire response range. The scale's reliability was seen within and across surgical specialties. Reliability was obtained from assessing a multitude of surgical procedural videos and coagulopathic conditions. A vast majority of surgeons agreed that the scale was relevant for evaluating hemostasis and that the range of bleeding site sizes and severities were appropriately represented.
Limitations. The validation of the scale was online and used videos depicting various bleeds, so use in a clinical setting can further support the scale's usability. Based on observational data in the validation phase, it is foreseeable that the scale will have high usability in the clinical setting. This is supported by all surgeons determining that the scale can be implemented for a clinical study and 99.0% of the surgeons determining that the scale is clinically relevant for evaluating hemostasis. The usability in the clinical setting may differ if the videos in the validation were not clinically relevant; however, all videos depicting an active bleed were considered to be clinically relevant by surgeons in the validation phase.
Visual estimations of blood loss are known to be inaccurate. [32] [33] [34] [35] [36] As seen in our study and in the literature, estimations improve after training and when volumes are generalized to a range. 36 Alternate techniques to estimate blood loss from a bleeding site include gravimetric, colormetric, photometry, spectrophotometry, and feature extraction imaging. 33, 37, 38 These traditional techniques have not proven valuable in the clinical setting due to the need for special equipment, the availability of staff, or the accuracy of the technique.
Feature extraction technology, however, is a recent advancement that measures hemoglobin loss in real time with a high degree of accuracy. [38] [39] [40] Hemoglobin loss, however, does not represent blood volume loss, which determines bleeding severity. The applicability of this technology is, therefore, limited in its use for determining bleeding severity.
Future research. In our study, intraobserver agreement was assessed using a short, test-retest period. The intraobserver agreement may worsen with a longer test-retest period. The reliability of the interobserver agreement in the feasibility and validation phases, however, demonstrates that surgeons use the scale in a consistent way. This suggests that the intraobserver agreement is not likely to be affected over long periods of time.
The surgical specialties selected to participate in this study are those that experience all levels of bleeding and are typically included in clinical studies investigating hemostatic agents. Based on the consistent agreement throughout all study phases among the included surgical specialties, the scale is likely to be broadly applicable to all surgical specialties. Data from the surgical specialties not included in the development and validation, however, would be further supportive of the scale's broad applicability.
While a majority of surgeons foresee that the scale is applicable to minimally invasive surgery "as is," a follow-up study is warranted to confirm reliability given the different environment, visibility (eg, magnification of bleeding, perception of bleeding), and physiologic effects (eg, hypertension secondary to insufflation, hypothermia secondary to nonhumidified or nonwarmed insufflation gases, decreased venous return, etc).
Further, minimally invasive surgery has a lower tolerance for blood loss. This may suggest that the rates of blood loss may need to be revised. Based on the scale of Siegel et al 24 for laparoscopic staplers, surgeons defined hemostasis as an oozing bleed that progresses for 15 seconds but does not require intervention. In comparison, this definition aligns to grade 0 "no bleeding" with a rate of blood loss of <1.0 mL/min. This suggests that the visually estimated rates of blood loss are translatable to minimally invasive surgery.
In conclusion, we document the development and validation of an intraoperative bleeding severity scale that fulfills FDA criteria for a CRS. This validated scale is an essential tool for use in clinical studies to standardize inclusion-exclusion criteria and to assess the performance of hemostatic agents in clinical studies of hemostatic agents. The scale is designed to generate labeling claims that are clinically relevant, which can
